EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy
This article was originally published in SRA
Executive Summary
Pharmaceutical companies in the EU should see conditional marketing authorization as a useful drug development planning tool, rather than as a "rescue option" to be used when they are unable to secure a full marketing authorization because they have not generated the required additional data, according to a senior European Commission official.
You may also be interested in...
Australian Provisional Approval Pathway To Get Tough On Sponsors Upfront
Plans by Australia’s Therapeutic Goods Administration to develop a provision approval pathway for drugs have moved up a gear.
Lilly’s Sarcoma Drug Lartruvo Latest To Test EU Conditional Approval System
Lartruvo, Lilly’s new drug for the rare condition soft tissue sarcoma, has been recommended for conditional marketing authorization in the EU pending the results of an ongoing Phase III study. The conditional approval system itself is under scrutiny regarding the fulfilment of obligations.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.